[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Niagen Bioscience Inc (NAGE)

Niagen Bioscience Inc (NAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 256,454
  • Shares Outstanding, K 79,644
  • Annual Sales, $ 129,420 K
  • Annual Income, $ 17,380 K
  • EBIT $ 11 M
  • EBITDA $ 12 M
  • 60-Month Beta 2.09
  • Price/Sales 2.02
  • Price/Cash Flow 16.22
  • Price/Book 3.18

Options Overview Details

View History
  • Implied Volatility 167.98% (-24.86%)
  • Historical Volatility 50.52%
  • IV Percentile 84%
  • IV Rank 14.22%
  • IV High 789.28% on 02/18/26
  • IV Low 64.95% on 09/11/25
  • Expected Move (DTE 21) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 70
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 5,608
  • Open Int (30-Day) 5,738
  • Expected Range 3.32 to 3.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.00
  • Number of Estimates 2
  • High Estimate $0.02
  • Low Estimate $-0.01
  • Prior Year $0.04
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.12 +6.58%
on 07/29/26
3.64 -8.79%
on 07/07/26
+0.13 (+4.08%)
since 06/30/26
3-Month
3.12 +6.58%
on 07/29/26
5.12 -35.17%
on 05/04/26
-1.41 (-29.81%)
since 04/30/26
52-Week
3.12 +6.58%
on 07/29/26
11.29 -70.59%
on 08/07/25
-6.21 (-65.16%)
since 07/30/25

Most Recent Stories

More News
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging

New epigenetic findings show Niagen NR reduces muscle biological aging and supports healthy muscle function

NAGE : 3.32 (+3.11%)
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer,...

NAGE : 3.32 (+3.11%)
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference...

NAGE : 3.32 (+3.11%)
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments

NAGE : 3.32 (+3.11%)
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

Virtual Q&A session to discuss the recently launched pharma program, the Company’s leadership in NAD+ science, and provide updates on Niagen Bioscience's business

NAGE : 3.32 (+3.11%)
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

NB4168, a patented therapeutic candidate designed to have significantly increased bioavailability and a differentiated safety and pharmacokinetic profile compared to NRC, is the first...

NAGE : 3.32 (+3.11%)
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will...

NAGE : 3.32 (+3.11%)
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen ® and advancing...

NAGE : 3.32 (+3.11%)
Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will...

NAGE : 3.32 (+3.11%)
Niagen Bioscience: Q1 Earnings Snapshot

Niagen Bioscience: Q1 Earnings Snapshot

NAGE : 3.32 (+3.11%)

Business Summary

Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 3.51
2nd Resistance Point 3.42
1st Resistance Point 3.37
Last Price 3.32
1st Support Level 3.23
2nd Support Level 3.14
3rd Support Level 3.09

See More

52-Week High 11.29
Fibonacci 61.8% 8.17
Fibonacci 50% 7.20
Fibonacci 38.2% 6.24
Last Price 3.32
52-Week Low 3.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.